Abstract

9644 Background: Intratumoral concentration of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) has been reported to be related to disease progression in patients with gastric cancer, however, prognostic significance of tumor TIMP-1 concentrations has not been clarified. Methods: Concentrations of TIMP-1 protein were measured by enzyme-linked immuno-sorbent assay in tumor samples of 86 patients who underwent gastric resection and were followed-up prospectively for 5 years. Tumor TIMP-1 concentrations≥10.0 ng/mg protein were considered positive.Results: Positive tumor TIMP-1 was observed in 31 of 86 patients (36.0%). Kaplan-Meier survival curves were significantly different between patients with positive and those with negative tumor TIMP-1. By univariate analyses of the factors affecting survival, the depth of tumor invasion in the gastric wall (T), the extent of lymph node metastasis (N), the presence of peritoneal dissemination, lymphatic invasion, venous invasion, Lauren classification of histology, and tumor TIMP-1were found to be significant. By step-wise multivariate analysis, T, N, peritoneal dissemination, and tumor TIMP-1 remained independent prognostic factor, although the statistics for T, N, and tumor TIMP-1 did not reach significance. Conclusions: Tumor TIMP-1 seemed to be one of significant prognosticator for the survival in patients with gastric cancer. No significant financial relationships to disclose.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.